Comparative Pharmacology
Head-to-head clinical analysis: BIVALIRUDIN versus IPRIVASK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIVALIRUDIN versus IPRIVASK.
BIVALIRUDIN vs IPRIVASK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bivalirudin is a direct thrombin inhibitor that binds reversibly to the active site of both free and clot-bound thrombin, inhibiting thrombin-mediated conversion of fibrinogen to fibrin and activation of factors V, VIII, and XIII.
Direct thrombin inhibitor; binds reversibly to the active site of free and clot-bound thrombin, inhibiting fibrin formation and activation of coagulation factors V, VIII, and XIII.
Initial intravenous bolus of 0.75 mg/kg, followed by continuous intravenous infusion at 1.75 mg/kg/hour for the duration of the procedure.
Adults: 1 mg/kg intravenously twice daily.
None Documented
None Documented
25 minutes (in patients with normal renal function); prolonged to ~57 minutes in severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderateBivalirudin + Benzydamine
"Bivalirudin may increase the anticoagulant activities of Benzydamine."
Clinical Note
moderateBivalirudin + Deferasirox
"The risk or severity of adverse effects can be increased when Bivalirudin is combined with Deferasirox."
Clinical Note
moderateBivalirudin + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Bivalirudin."
Clinical Note
moderateBivalirudin + Droxicam
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment; up to 6 hours in severe impairment).
Renal: 20% unchanged; proteolytic cleavage (hepatic and other sites) accounts for the remainder.
Renal: 70% as unchanged drug; biliary/fecal: 30% (metabolites and unchanged drug).
Category C
Category C
Direct Thrombin Inhibitor
Direct Thrombin Inhibitor
"Bivalirudin may increase the anticoagulant activities of Droxicam."